<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633892</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12010078</org_study_id>
    <nct_id>NCT01633892</nct_id>
  </id_info>
  <brief_title>Use of Concentrated Endogenous Autologous Adipose Stromal Cells in Fat Grafts for Craniofacial Trauma</brief_title>
  <acronym>ARM5</acronym>
  <official_title>Use of Concentrated Endogenous Autologous Adipose Stromal Cells in Fat Grafts for Craniofacial Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic facial injuries, especially those sustained in military combat, are characterized
      by destruction of bone and soft tissue. While the bony structures of the face can be
      reconstructed, it is difficult to return the soft tissue back to its original form. Many
      times, fat grafting, a common cosmetic and reconstructive procedure, is used in hopes of
      improving the soft tissue deformity. Fat grafting is a procedure in which a person's own fat
      is taken from areas throughout the body, usually the thighs or abdomen, with a small
      liposuction tube. The fat is then transferred into the area that has lost volume or fullness.
      The fullness of the soft tissue area may decrease over time because the transferred fat can
      be reabsorbed by the body. Altering the current fat grafting procedure, slightly, could lead
      to less reabsorption and a lasting fullness of the soft tissue area outcome of the fat graft
      procedure.

      The investigators are conducting this research study to help us improve the surgical
      treatment of people who have suffered facial soft tissue loss as a result of trauma. The goal
      of this research study is to see how each person's fat grafts will maintain the fat over time
      and to measure the quality of life during a 9 month post-surgical follow-up period. The total
      duration of participation is approximately 11-12 months. In this study, the investigators
      will concentrate the fat in the fat grafting procedure to determine whether this process will
      maintain the fat over time. The areas treated with enhanced fat grafts will be compared with
      areas treated with standard of care fat grafts. At least two areas of your face will be
      treated with fat grafts, (standard of care fat grafts and concentrated fat grafts).

      This study is the second of two clinical studies at the University of Pittsburgh using each
      person's fat graft with concentration of fat cells in the graft to observe if there is less
      fat resorption compared to using fat grafts alone. Each study is using a different
      concentration of fat in the fat graft compared to the first clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Craniofacial injuries have serious psychosocial sequele and affect quality of life. Many
      individuals who suffer significant facial disfigurement from injury experience psychological
      distress and impairment in functioning not limited to the acute phase of injury, but over a
      longer term period of treatment, recovery, and adjustment. Until recently, treatment of
      disfiguring craniofacial injuries has been mostly limited to surgical flap procedures,
      microsurgical tissue transfer, and implantable prostheses. However, these methods can leave
      conspicuous scars on the face and the donor site, and in the case of implants can lead to
      complications associated with foreign materials. Autologous fat grafting with minimally
      invasive cannulas is a procedure that has been used for decades in common plastic surgery
      practice for facial aesthetic procedures. This technique is also a promising treatment for
      soft tissue reconstruction after craniofacial trauma because the graft harvest and injection
      are minimally invasive. The treatment is performed by using a small liposuction cannula to
      aspirate fat tissue from the donor site, and then re-injecting the fat into the recipient
      site with specialized injection cannulas. After harvest, and prior to injection, the fat
      graft is subjected to a mechanical processing step to separate the aqueous layer and
      concentrate the adipocytes. This often takes the form of centrifugation or filtering.

      The main problem with autologous fat grafting is a variable resorption of the graft volume
      over time. As much as 30-60% of the graft volume can diminish over time. Many variables may
      influence the behavior of clinical fat grafts, including harvest site, harvest technique,
      graft preparation, and injection technique.

      Concentrating the already present autologous adipose stromal cells within the fat grafts is
      not expected to increase subject risk levels beyond the risk levels of the application of fat
      grafts. We are currently approved for the application of fat grafts with concentrated
      autologous adipose stromal cells [IRB#10100293]. This proposal uses an increased
      concentration of adipose stromal cells compared to the above referenced study; no increase of
      risk to the subject is anticipated. We hypothesize that fat grafting for facial trauma,
      facilitated by enhancing graft quality with a higher concentration of endogenous autologous
      vascular adipose stromal cells in the grafted tissue, will enhance the successful restoration
      of tissue volume and craniofacial form. The use of a higher concentration of autologous
      adipose stromal cells may lead to lower fat resorption rates that may be observed in the
      approved IRB study [PRO10100293]. Additionally, we hypothesize that the clinical results
      using the concentrated autologous stromal vascular cells will be durable and the subject's
      quality of life scores will be improved compared to subjects who have had fat grafting alone
      using historical controls.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding ended
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Fat Graft Volume Facial Form From Baseline up to 9 Months</measure>
    <time_frame>0, 1, 3, and 9 months</time_frame>
    <description>High resolution CT scanning with 3D reconstruction at 0, 1, 3, and 9 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Tissue Thickness From Baseline up to 9 Months</measure>
    <time_frame>0, 1, 3, and 9 months</time_frame>
    <description>High resolution CT scanning with 3D reconstruction at 0, 1, 3, and 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure Quality of Life in Subjects After Grafting Using Validated Psychosocial Measures.</measure>
    <time_frame>9 months</time_frame>
    <description>1) Social Avoidance and Distress Scale (SADS) uses a questionnaire including 28 true/false items, with scores ranging from 0-10. A &quot;low&quot; score is below 4, &quot;high&quot; is above 7; intermediate is between 4-7. 2) COPE scale asks the subject to indicate what he/she generally does and feels, when he/she experience stressful events. On a scale of 60-240 where the higher ends indicates the subject does this activity most frequently during stressful events; 3) The Satisfaction With Appearance Scale (SWAP) is a 14-item questionnaire, assessing both the subjective appraisal and social-behavioral components of body image, where the higher the score, the more satisfied subject is with procedure, ranging from 0-7 for a total possible score range between 0-98 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of SVF</measure>
    <time_frame>time of fat grafting, up to 12 hours post-baseline</time_frame>
    <description>Cell assessment included stromal vascular fraction composition evaluated by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Adipose Stromal Cell (ASC) Function</measure>
    <time_frame>time of surgery, up to 12 hours post-baseline</time_frame>
    <description>Cell assessment will include viable stromal vascular fraction per gram of lipoaspirate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Craniofacial Injuries</condition>
  <arm_group>
    <arm_group_label>Fat Grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fat Grafting</intervention_name>
    <arm_group_label>Fat Grafting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 years or older and able to provide informed consent.

          2. Have suffered injury resulting in craniofacial volume defects which could be treated
             with a graft volume of between 3 and 100 cc of lipoaspirate

          3. Be at least 3 months post-injury or post-surgery (from trauma procedures) so that
             acute edema is resolved

          4. Volume defects are covered by intact skin and do not communicate with oral cavity or
             sinuses

          5. The three dimensional geometry of the volume defects would allow for treatment with
             lipoaspirate injection so that at least two distinct treated areas could be discerned
             on gross examination and radiographically (e.g. treated regions are on opposite sides
             of the face, on lower face versus upper face, or separated by a bony landmark such as
             zygoma. This would include the ability to treat an uninjured regions with fat grafts
             in order to obtain symmetry or balance.

          6. Willing and able to comply with follow up examinations,

        Exclusion Criteria:

          1. Age less than 18 years

          2. Inability to provide informed consent

          3. Craniofacial defects intended for treatment have open wounds or communicate with oral
             cavity or sinus (note: presence of such a defect in the setting of another defect(s)
             that meets treatment criteria will not exclude the patient from participating).

          4. Active infection anywhere in the body

          5. Diagnosed with cancer within the last 12 months and/or presently receiving
             chemotherapy or radiation treatment

          6. Known coagulopathy

          7. Systemic disease that would render the fat harvest and injection procedure, along with
             associated anesthesia, unsafe to the patient.

          8. Pregnancy

          9. Diagnosis of Schizophrenia or Bipolar Disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Peter Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg. 2008 Jan;32(1):48-55; discussion 56-7. Epub 2007 Sep 1.</citation>
    <PMID>17763894</PMID>
  </reference>
  <reference>
    <citation>Masuda T, Furue M, Matsuda T. Novel strategy for soft tissue augmentation based on transplantation of fragmented omentum and preadipocytes. Tissue Eng. 2004 Nov-Dec;10(11-12):1672-83.</citation>
    <PMID>15684676</PMID>
  </reference>
  <reference>
    <citation>Matsumoto D, Sato K, Gonda K, Takaki Y, Shigeura T, Sato T, Aiba-Kojima E, Iizuka F, Inoue K, Suga H, Yoshimura K. Cell-assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. Tissue Eng. 2006 Dec;12(12):3375-82.</citation>
    <PMID>17518674</PMID>
  </reference>
  <reference>
    <citation>Moseley TA, Zhu M, Hedrick MH. Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):121S-128S. Review.</citation>
    <PMID>16936551</PMID>
  </reference>
  <reference>
    <citation>Lu F, Li J, Gao J, Ogawa R, Ou C, Yang B, Fu B. Improvement of the survival of human autologous fat transplantation by using VEGF-transfected adipose-derived stem cells. Plast Reconstr Surg. 2009 Nov;124(5):1437-46. doi: 10.1097/PRS.0b013e3181babbb6.</citation>
    <PMID>20009828</PMID>
  </reference>
  <reference>
    <citation>Zhu M, Zhou Z, Chen Y, Schreiber R, Ransom JT, Fraser JK, Hedrick MH, Pinkernell K, Kuo HC. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg. 2010 Feb;64(2):222-8. doi: 10.1097/SAP.0b013e31819ae05c.</citation>
    <PMID>20098110</PMID>
  </reference>
  <reference>
    <citation>Yoshimura K, Asano Y, Aoi N, Kurita M, Oshima Y, Sato K, Inoue K, Suga H, Eto H, Kato H, Harii K. Progenitor-enriched adipose tissue transplantation as rescue for breast implant complications. Breast J. 2010 Mar-Apr;16(2):169-75. doi: 10.1111/j.1524-4741.2009.00873.x. Epub 2009 Nov 12.</citation>
    <PMID>19912236</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <results_first_submitted>May 12, 2016</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>J. Peter Rubin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Craniomaxillofacial (CMF)</keyword>
  <keyword>Battle-injured (BI)</keyword>
  <keyword>Facial Trauma</keyword>
  <keyword>Fat Grafts</keyword>
  <keyword>Autogenous Fat Transfers (AFT)</keyword>
  <keyword>Wounded warriors</keyword>
  <keyword>Adipose Tissue</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fat Grafting</title>
          <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fat Grafting</title>
          <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Volume (cc)</title>
          <units>cc</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Thickness (mm)</title>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Fat Graft Volume Facial Form From Baseline up to 9 Months</title>
        <description>High resolution CT scanning with 3D reconstruction at 0, 1, 3, and 9 months</description>
        <time_frame>0, 1, 3, and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fat Grafting</title>
            <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Fat Graft Volume Facial Form From Baseline up to 9 Months</title>
          <description>High resolution CT scanning with 3D reconstruction at 0, 1, 3, and 9 months</description>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Tissue Thickness From Baseline up to 9 Months</title>
        <description>High resolution CT scanning with 3D reconstruction at 0, 1, 3, and 9 months</description>
        <time_frame>0, 1, 3, and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fat Grafting</title>
            <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Tissue Thickness From Baseline up to 9 Months</title>
          <description>High resolution CT scanning with 3D reconstruction at 0, 1, 3, and 9 months</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.62" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.62" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Quality of Life in Subjects After Grafting Using Validated Psychosocial Measures.</title>
        <description>1) Social Avoidance and Distress Scale (SADS) uses a questionnaire including 28 true/false items, with scores ranging from 0-10. A &quot;low&quot; score is below 4, &quot;high&quot; is above 7; intermediate is between 4-7. 2) COPE scale asks the subject to indicate what he/she generally does and feels, when he/she experience stressful events. On a scale of 60-240 where the higher ends indicates the subject does this activity most frequently during stressful events; 3) The Satisfaction With Appearance Scale (SWAP) is a 14-item questionnaire, assessing both the subjective appraisal and social-behavioral components of body image, where the higher the score, the more satisfied subject is with procedure, ranging from 0-7 for a total possible score range between 0-98 .</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fat Grafting</title>
            <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Quality of Life in Subjects After Grafting Using Validated Psychosocial Measures.</title>
          <description>1) Social Avoidance and Distress Scale (SADS) uses a questionnaire including 28 true/false items, with scores ranging from 0-10. A &quot;low&quot; score is below 4, &quot;high&quot; is above 7; intermediate is between 4-7. 2) COPE scale asks the subject to indicate what he/she generally does and feels, when he/she experience stressful events. On a scale of 60-240 where the higher ends indicates the subject does this activity most frequently during stressful events; 3) The Satisfaction With Appearance Scale (SWAP) is a 14-item questionnaire, assessing both the subjective appraisal and social-behavioral components of body image, where the higher the score, the more satisfied subject is with procedure, ranging from 0-7 for a total possible score range between 0-98 .</description>
          <units>units on a scale, see outcome measure de</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SADS Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composition of SVF</title>
        <description>Cell assessment included stromal vascular fraction composition evaluated by flow cytometry.</description>
        <time_frame>time of fat grafting, up to 12 hours post-baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fat Grafting</title>
            <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Composition of SVF</title>
          <description>Cell assessment included stromal vascular fraction composition evaluated by flow cytometry.</description>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Endothelial Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.76" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Pericytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.91" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Supradventitial Stromal Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Adipose Stromal Cell (ASC) Function</title>
        <description>Cell assessment will include viable stromal vascular fraction per gram of lipoaspirate.</description>
        <time_frame>time of surgery, up to 12 hours post-baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fat Grafting</title>
            <description>Fat Grafting procedure designed to deliver an autologous fat graft admixed with autologous stromal vascular fraction (SVF) at a high cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Adipose Stromal Cell (ASC) Function</title>
          <description>Cell assessment will include viable stromal vascular fraction per gram of lipoaspirate.</description>
          <units>mL of viable SVF per g of lipoaspirate</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.444" spread="1.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fat Grafting</title>
          <description>Autologous fat grafting is a potential solution. Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 5mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the donor site. This surgical procedure involves the immediate transplantation of a patientâ€™s own tissue in a single operative procedure. It has the advantages of:
Minimal access incisions
Ability to transfer significant amounts of tissue (hundreds of grams of tissue)
Can be used in setting of previous surgical procedures and presence of hardware
Usually performed as outpatient procedure
Minimal donor site morbidity at graft harvest site
Low risk compared with more invasive surgical procedures
Can be repeated multiple times, if necessary, even using the same donor site</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>J. Peter Rubin</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-624-9703</phone>
      <email>rubipj@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

